4.8 Article

Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 125, Issue 2, Pages 681-686

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI78421

Keywords

-

Funding

  1. NIH [P30AG036453, K08NS072235, R01CA159227, R01MH080442, R01N5069695, P50AG08702, R01AG037212, P01AG07232, R01NS042859, P30AG028383, P50AG05131, U24NS072026, P30AG19610]
  2. Alzheimer's Association [NIRG-11-204450]
  3. Louis V. Gerstner Jr. Foundation
  4. Howard Hughes Medical Institute (HHMI)
  5. BrightFocus Foundation
  6. Arizona Department of Health Services
  7. Arizona Biomedical Research Commission
  8. Michael J. Fox Foundation
  9. Medical Research Council [G0902418] Funding Source: researchfish
  10. MRC [G0902418] Funding Source: UKRI

Ask authors/readers for more resources

Tau is a highly abundant and multifunctional brain protein that accumulates in neurofibrillary tangles (NFTs), most commonly in Alzheimer's disease (AD) and primary age-related tauopathy. Recently, microRNAs (miRNAs) have been linked to neurodegeneration; however, it is not clear whether miRNA dysregulation contributes to tau neurotoxicity. Here, we determined that the highly conserved brain miRNA miR-219 is downregulated in brain tissue taken at autopsy from patients with AD and from those with severe primary age-related tauopathy. In a Drosophila model that produces human tau, reduction of miR-219 exacerbated tau toxicity, while overexpression of miR-219 partially abrogated toxic effects. Moreover, we observed a bidirectional modulation of tau levels in the Drosophila model that was dependent on miR-219 expression or neutralization, demonstrating that miR-219 regulates tau in vivo. In mammalian cellular models, we found that miR-219 binds directly to the 3'-UTR of the tau mRNA and represses tau synthesis at the post-transcriptional level. Together, our data indicate that silencing of tau by miR-219 is an ancient regulatory mechanism that may become perturbed during neurofibrillary degeneration and suggest that this regulatory pathway may be useful for developing therapeutics for tauopathies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available